Journal
THROMBOSIS AND HAEMOSTASIS
Volume 113, Issue 1, Pages 165-176Publisher
GEORG THIEME VERLAG KG
DOI: 10.1160/TH14-04-0332
Keywords
Haemophilia; prolonged half-life; coagulation factors
Categories
Funding
- CSL Behring
Ask authors/readers for more resources
The use of plasma-derived and recombinant coagulation factors for the treatment of haemophilia A and B is well established and permits patients to live a relatively normal life. In order to improve treatment options, several products are in development, which have a prolonged duration of action, thus enabling less frequent prophylactic dosing and aiming to reduce the burden of treatment. Several innovative approaches are being pursued to extend the half-life of factor Vila, factor VIII and factor IX, utilising technologies such as Fe fusion, recombinant albumin fusion and addition of polyethyleneglycol (PEG) (PEGylation). These methods prolong the time in the circulation by reducing degradation and elimination. This review summarises the technologies and products in development and their stages of development, and also discusses their pros and cons.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available